Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model

Journal of Chemical Neuroanatomy

Volumn 71, Issue , 2016, Pages 41-49

  Rai, Sachchida Nand ^a   Yadav, Satyndra Kumar ^a   Singh, Divakar ^a   Singh, Surya Pratap ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

3,4 Dihydroxyphenylacetic acid; Dopaminergic neuron; Homovanilic acid; Substantia nigra; Tyrosine hydroxylase; Ursolic acid

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; NEUROPROTECTIVE AGENT; TRITERPENE; TYROSINE 3 MONOOXYGENASE; URSOLIC ACID;

ANIMAL; ANIMAL BEHAVIOR; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFECTS; MALE; METABOLISM; MOUSE; OXIDATIVE STRESS; PARKINSON DISEASE; PSYCHOLOGY; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DOPAMINE; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMOVANILLIC ACID; MALE; MICE; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; PARS COMPACTA; SUBSTANTIA NIGRA; TRITERPENES; TYROSINE 3-MONOOXYGENASE;

EID: 84952883560     PISSN: 08910618     EISSN: 18736300     Source Type: Journal    
DOI: 10.1016/j.jchemneu.2015.12.002     Document Type: Article

References (77)

1. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., Jenner P., Halliwell B. Oxidative DNA damage in the Parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 1997, 69:1196-1203.
2. Ali S.M., Ibrahim Syed A., Jalil Saima, Choudhary Muhammad I. Ursolic acid: a potent inhibitor of superoxides produced in the cellular system. Phytother. Res. 2007, 21:558-561.
3. An L.J., Guan S., Shi G.F., Bao Y.M., Duan Y.L., Jiang B. Protocatechuic acid from Alpinia oxyphylla against MPP+-induced neurotoxicity in PC12 cells. Food. Chem. Toxicol. 2006, 44:436-443.
4. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat. Med. 2004, 10:S18-S25.
5. Andersen Julie K. Oxidative stress in neurodegeneration: cause or consequence?. Nat. Rev. Neurosci. 2004, 5:S18-S25.
6. Arral Z., Amit T., youdim B.H.M., Farah R. Lithium and oxidative stress lessons from the MPTP model of Parkinson's disease. Neurosci. Lett. 2012, 1:57-61.
7. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 2005, 58:495-505.
8. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury nitric oxide and superoxide. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:1620-1624.
9. Blum D., Torch S., Lambeng N., Nissou M., Benabid A., Sadoul R., Verna J. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65:135-172.
10. Butler A.R., Flitney F.W., Williams D.L.H. NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemists perspective. Trends. Pharmacol. Sci. 1995, 16:18-22.
11. Flora Iberica vol, 1, 1986 (LIV+ 575 pp) and vol. 2, 1990 (LII+ 897 pp.) 1990, Real Jardin Botanico C. S. I. C, Madrid. S. Castroviejo (Ed.).
12. Chiba K., Trevor A., Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 1984, 120:574-578.
13. Chinta S.J., Rajagopalan S., Butterfield D.A., Andersen J.K. In vitro and in vivo neuroprotection by γ-glutamylcysteine ethylester against MPTP: relevance to the role of glutathione in Parkinson's disease. Neurosci. Lett. 2006, 402:137-141.
14. Chitra K.C., Latchoumycandane C., Mathur P.P. Induction of oxidative stress by bisphenol A in the epididymal sperm of rats. Toxicology 2003, 14:119-127.
15. Conboy L., Varea E., Castro J.E., Sakouhi-Ouertatani H., Calandra T., Lashuel H.A., Sandi C. Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferationand in anxiety, depression, and memory-related behaviors. Mol. Psychiatry 2011, 16(5):533-547.
16. Dick F.D. Parkinson's disease and pesticide exposures. Br. Med. Bull. 2006, 79-80:219-231.
17. Fahn S., Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004, 1:139-154.
18. Floor E., Wetzel M. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 1998, 70:268-275.
19. Fukushima T., Gao T., Tawara T., Hojo N., Isobe A., Yamane Y. Inhibitory effect of nicotinamide to paraquat toxicity and the reaction site on complex I. Arch. Toxicol. 1997, 71:633-637.
20. Gorbatyuk O.S., Li S., Sullivan L.F., Chen W., Kondrikova G., Manfredsson F.P., Mandel R.J., Muzyczka N. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:763-768.
21. Granger D.L., Taintor R.R., Boockvar K.S., Hibbs J.B. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Greiss reaction. Methods Enzymol. 1996, 268:142-151.
22. Halliwell B., Gutteridge J.M.C. Oxygen radicals and the nervous system. Trends Neurosci. 1985, 8:22-29.
23. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine 1999, Oxford University Press, London. third ed.
24. Heather Mortiboys, Jan Aasly, Oliver Bandmann Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Brain 2013, 136:3038-3050.
25. Hinterberger H. The biochemistry of catecholamine in relation to Parkinson's disease. Aust. N.Z. J. Med. 1971, 1:14-18.
26. Ischiropoulos H., Zhu L., Chen J., Tsai M., Martin J.C., Smith C.D., Beckman J.S. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 1992, 298:431-437.
27. Jackson-Lewis V., Smeyne R.J. MPTP and SNpc DA neuronal vulner-ability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Neurotoxicol. Res. 2005, 7:193-202.
28. Jenner P., Olanow W. The pathogenesis of cell death in Parkinson's disease. Neurology 2006, 66:S24-S36.
29. Kim Ji Ho, Kim Gun Hee, Hwang Keum Hee Monoamine oxidase and dopamine β-hydroxylase inhibitors from the fruits of gardenia jasminoides. Biomole. Ther. 2012, 20(2):214-219.
30. Jin A., Lee H.G., Zhu X., Takeda A., Perry G., Simth M.A. Emerging evidence for the neuroprotective role of α-synuclein. Exp. Neurol. 2006, 200:1-7.
31. Keene C.D., Rodrigues C.M., Eich T., Chhabra M.S., Steer C.J., Low W.C. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10671-10676.
32. Kim C., Speisky M.B., Kharouba S.N. Rapid and sensitive method for measuring norepinephrin, dopamine, 5-hydroxytryp-tamine and their major metabolites in rat brain by high performance liquid chromatography. J. Chromatogr. 1987, 386:25-35.
33. Krishnamurthy S., Garabadu D., Reddy N.R., Joy K.P. Risperidone in ultra low dose protects against stress in the rodent cold restraint model by modulating stress pathways. Neurochem. Res. 2011, 36:1750-1758.
34. Kumar A., Ahmad I., Shukla S., Singh B.K., Patel D.K., Pandey H.P., Singh C. Effect of zinc and PQ co-exposure on neurodegeneration: modulation of oxidative stress and expression of metallothioneins, toxicant responsive and transporter genes in rats. Free Radical Res. 2010, 44(8):1-16.
35. Lee J.K., McCoy M.K., Harms A.S., Ruhn K.A., Gold S.J., Tansey M.G. Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. J. Neurosci. 2009, 28:8517-8528.
36. Lee J.M., Hwanga D.S., Kim H.G., Lee C.H., Oh M.S. Dangguijakyak-san protects dopamine neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity under postmenopausal conditions. J. Ethnopharmacol. 2012, 139:883-888.
37. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
38. Lindvall O., Kokaia Z. Stem cells for the treatment of neurological disorders. Nature 2006, 441(7097):1653-1661.
39. Liu J. J. Ethnopharmacol. 1995, 49:57-68.
40. Lu J., Zheng Y.L., Wu D.M., Luo L., Sun D.X., Shan Q. Ursolic acid ameliorates cognition deficits and attenuates oxidative damage in the brain of senescent mice induced by d-galactose. Biochem. Pharmacol. 2007, 74:1078-1090.
41. Manna S., Bhattacharyya D., Mandal T.K., Dey S. Neurophar-macological effects of deltamethrin in rats. J. Vet. Sci. 2006, 7:133-136.
42. Mishra L.C., Singh B.B., Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern. Med. Rev. 2000, 5:334-346.
43. Mochizuki H., Hayakawa H., Migita M., Shibata M., Tanaka R., Suzuki A., Shimo-Nakanishi Y., Urabe T., Yamada M., Tamayose K., Shimada T., Miura M., Mizuno Y. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10918-10923.
44. Mochizuki H., Yasuda T. Iron Accumulation in Parkinson's disease. J. Neural. Transm. 2012, 119:1511-1514.
45. Mohanasundari M., Srinivasan M.S., Sethupathy S., Sabesan M. Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice. J. Neurol. Sci. 2006, 249:140-144.
46. Napoli M.Di, Shah I.M., Stewart D.A. Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside. Expert Rev. Neurother. 2007, 7:1693-1729.
47. Neto C.C., Amoroso J.W., Liberty A.M. Mol. Nutr. Food Res. 2008, 52(Suppl 1):S18-S27.
48. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95:351-358.
49. Patil R., Gholave A., Jadhav J., Yadav S., Bapat V. Mucuna sanjappae-a new species of Mucuna with promising yield of anti-Parkinson's drug l-DOPA. Genet. Resour. Crop. Evol. 2014, 10.1007/s10722-014-0164-8.
50. Pifl C., Giros B., Caron M.G. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J. Neurosci. 1993, 13:4246-4253.
51. Piggott M.A., Marshall E.F., Thomas N., Lloyd S., Court C.A., Jaros E., Burn D., Johnson M., Perry R.H., McKeith I.G., Ballard C., Perry E.K. Striatal dopaminergic markers in dementia with lewy bodies. Alzheimer's disease and Parkinson's diseases rostracaudal distribution. Brain 1999, 122:1449-1468.
52. Pisa M. Regional specialization of motor functions in the rat striatum: implications for the treatment of Parkinsonism. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1998, 12:217-224.
53. Raja Sankar S., Manivasagam T., Sankar V., Prakash S., Muthusamy R., Krishnamurti A., Surendran S. Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse. J. Ethnopharmacol. 2009, 125:369-373.
54. Ramalho R.M., Viana R.J., Low W.C., Steer C.J., Rodrigues C.M. Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease. Trends Mol. Med. 2008, 14:54-62.
55. Richardson J.R., Quan Y., Sherer T.B., Greenamyre J.T., Miller G.W. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol. Sci. 2005, 88:193-201.
56. Rodrigues C.M., Sola S., Nan Z., Castro R.E., Ribeiro P.S., Low W.C. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6087-6092.
57. Sadrzadeh S.M.H., Saffari Y. Iron and brain disorders. Am. J. Clin. Pathol. 2004, 121:64-70.
58. Sasaki M., Nakamura H., Tsuchiya S., Horie S., Kashiwayanagi M., Saito T., Murayama T. Quercetin-induced PC12 cell death accompanied by caspase-mediated DNA fragmentation. Biol. Pharm. Bull. 2007, 30:682-686.
59. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2008, 7:97-109.
60. Schapira A.H., Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov. Disord. 2011, 26:1049-1055.
61. Schulz J.B., Matthews R.T., Muqit M.M. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 1995, 64:936-939.
62. Shih Y.H., Chein Y.C., Wang J.Y., Fu Y.S. Ursolic acid protects hippocampal neurons against kainate-induced excitotoxicity in rats. Neurosci. Lett. 2004, 362:136-140.
63. Singh A.K., Tiwari M.N., Dixit A., Upadhyay G., Patel D.K., Singh D., Prakash O., Singh M.P. Nigrostriatal proteomics of cypermethrin-induced dopaminergic neurodegeneration: microglial activation-dependent and independent regulations. Toxicol. Sci. 2011, 122(2):526-538.
64. Singh S., Singh K., Patel D.K., Singh C., Nath C., Singh V.K., Singh R.K., Singh M.P. The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease phenotype and nicotine mediated neuroprotection. Rejuvenation. Res. 2009, 12:185-197. (12 Yadav, S.K., et al., 2014. Neurochem. Int. 65, 1-13).
65. Sulzer D., Surmeier D.J. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov. Disord. 2013, 28:41-50.
66. Sweeney P.J. Parkinson's disease: managing symptoms and preserving function. Geriatrics 1995, 50:24-31.
67. Tsang K.L., Ho S.L., Lo S.K. Estrogen improves motor disability in Parkinsonian postmenopausal women with motor fluctuations. Neurology 2000, 54:2292-2298.
68. Velayati A., Yu W.H., Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr. Neurol. Neurosci. Rep. 2010, 10:190-198.
69. Vyas I., Heikkila R.E., Nicklas W.J. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J. Neurochem. 1986, 46:1501-1507.
70. Wang Y.J., Lu J., Wu D.M., Zheng Z.H., Zheng Y.L., Wang X.H., Ruan J., Sun X., Shan Q., Zhang Z.F. Ursolic acid attenuates lipopolysaccharide-induced cognitive deficits in mouse brain through suppressing p38/NF-κB mediated inflammatory pathways. Neurobiol. Learn. Mem. 2011, 96:156-165.
71. Wilkinson K., Boyd J.D., Glicksman M., Moore K.J., El Khoury J. A high content drug screen identifies ursolic acid as an inhibitor of amyloid β protein interactions with its receptor CD36. J. Biol. Chem. 2011, 286:34914-34922.
72. Wooten G.F. Neurochemistry and neuropharmacology of Parkinson's disease. Movement disorders: neurologic principles and practice 1997, 153-160. McGraw-Hill, New York, NY. R.L. Watts (Ed.).
73. Wu Dong-mei, Lu Jun, Zhang Yan-qiu, Zheng Yuan-lin, Hu Bin, Cheng Wei, Zhang Zi-feng, Li Meng-qiu Ursolic acid improves domoic acid-induced cognitive deficits in mice. Toxicol. Appl. Pharmacol. 2013, 271(2):127-136.
74. Yadav S.K., Prakash J.P., Chouhan S., Singh S.P. Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model. Neurochemistry. Int. 2013, 62:1039-1047.
75. Yin M.C., Lin M.C., Mong M.C., Lin C.Y. Bioavailability, distribution, and antioxidative effects of selected triterpenes in mice. J. Agric. Food. Chem. 2012, 60:7697-7701.
76. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:2696-2701.
77. Zhu J., Chu C.T. Mitochondrial dysfunction in Parkinson's disease. J. Alzheimers. Dis. 2010, 20:S325-S334.